Detection of EGFR T790M, BRAF V600E, and PIK3CA E545K mutations became negative in April 2020, while EGFR E746_A750del despite marginally positive, presented marked reduction (Fig. 1b) suggesting that combination dabrafenib, trametinib, and osimertinib might be an effective strategy to overcome PIK3CA E545K and BRAF V600E-driven resistance to osimertinib in advanced EGFR-mutant NSCLC patients. Here, BRAF is linked to non-small cell lung carcinoma.